Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Meldola – page 34

443 clinical trials in Meldola, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Meldola at a glance
443
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

443 trials in Meldola

Open in trial search

Myelofibrosis

Not recruiting

Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Non-small cell lung cancer

Not recruiting

Study of Zipalertinib with Chemotherapy vs. Chemotherapy Alone for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Taiho Oncology Inc.

Endometrial cancer+1

Not recruiting

Study of Retifanlimab Alone and in Combination with Drug Therapy for Adults with Advanced or Metastatic Endometrial Cancer Who Have Not Responded to Platinum Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pemigatinib
  • Sponsor:Incyte Corp.

Hormone receptor positive breast cancer+1

Not recruiting

Study of Giredestrant, Triptorelin, and Anastrozole in Premenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:ETOP IBCSG Partners Foundation

Marginal zone lymphoma

Not recruiting

Study on [68Ga]Ga-PentixaFor and [18F]FDG PET/CT Imaging for Staging Marginal Zone Lymphoma in Patients with Confirmed Diagnosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68GA)
  • Sponsor:Pentixapharm AG

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Telisotuzumab Vedotin for Patients with Previously Treated c-Met Positive Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Telisotuzumab Vedotin
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer

Not recruiting

Study Comparing Pembrolizumab and Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study on the Effectiveness and Safety of CAM2029 Compared to Octreotide and Lanreotide in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Camurus AB

Adenocarcinoma gastric

Not recruiting

Study on the Effectiveness and Safety of Lenvatinib, Pembrolizumab, and Chemotherapy for Patients with Advanced or Metastatic Gastroesophageal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Transitional cell cancer of the renal pelvis and ureter

Not recruiting

Study of Sacituzumab Govitecan for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Gilead Sciences Inc.

Malignant melanoma

Not recruiting

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Meldola

What the registry says about research in the country

01 Hematologic Malignancies

Innovative research focusing on blood cancers, including studies of novel therapeutic combinations for acute myeloid leukemia, multiple myeloma, and various lymphomas.

  • Advanced treatments for diffuse large B-cell lymphoma
  • Multiple myeloma therapies for transplant-ineligible patients
  • Novel approaches in myelodysplastic syndrome

Studies are evaluating targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Solid Tumors

Comprehensive research into advanced solid tumors, with particular emphasis on colorectal cancer, non-small cell lung cancer, and breast cancer.

  • Targeted therapies for metastatic colorectal cancer
  • Novel combinations for advanced NSCLC
  • Innovative approaches in metastatic breast cancer

Investigations focus on personalized treatment strategies and novel drug combinations.

03 Genitourinary Cancers

Groundbreaking studies in urological cancers, including research on prostate cancer, urothelial cancer, and renal cell carcinoma.

  • Advanced treatments for metastatic prostate cancer
  • Maintenance therapy in urothelial cancer
  • Immunotherapy approaches in renal cell carcinoma

Research aims to improve survival rates through innovative therapeutic strategies.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.